Endoglin Is a Better Marker than CD31 in Evaluation of Angiogenesis in Glioblastoma

Behrem, Senija; Žarković, Kamelija; Eškinja, Neven; Jonjić, Nives
June 2005
Croatian Medical Journal;2005, Vol. 46 Issue 3, p417
Academic Journal
Aim To compare endoglin (CD105) and the pan-endothelial marker CD31 in the assessment of angiogenesis in glioblastoma and to evaluate their values in the prognosis of this malignancy. Methods Forty-six cases of glioblastoma were included in this retrospective study. All cases were immunohistochemically stained for endoglin (CD105), CD31, vascular endothelial growth factor (VEGF), and MIB-1 (Ki67). In order to assess microvessel density, positively stained microvessels were counted for each specimen in predominantly vascular areas (hot spot) at x400 magnification. The intensity of VEGF staining was scored on a three-tiered scale. The proliferation index was expressed as a percentage of Ki67 positive cells. Results Median CD105 microvessel density (median 49 microvessels/field, range 27-99) was significantly higher than median CD31 microvessel density (median 37 microvessels/field, range 12-76). CD105 microvessel density was more closely correlated with VEGF (Spearman's ρ = 0.421, P = 0.003) than with CD31 microvessel density (ρ = 0.330, P = 0.024). The proliferation index was significantly associated with CD105 microvessel density (Pearson's r = 0.323, P = 0.028), whereas correlation could not be observed with CD31 microvessel density (r = 0.219, P = 0.142). Finally, patients with lower CD105 microvessel density had a longer survival than those with higher CD105 microvessel density (P = 0.045), whereas CD31 microvessel density had no influence on the survival time (P = 0.340). Conclusion CD105 is a more sensitive marker than CD31 in the evaluation of angiogenesis in glioblastoma. Our study is the first report of the better prognostic significance of angiogenesis evaluated with CD105 rather than with CD31 in glioblastoma.


Related Articles

  • Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Shukla, Bhaskar; Agarwal, Shipra; Suri, Vaishali; Pathak, Pankaj; Sharma, Mehar Chand; Gupta, Deepak; Sharma, Bhavani Shankar; Suri, Ashish; Halder, Ashutosh; Sarkar, Chitra // Neurology India;Sep2009, Vol. 57 Issue 5, p559 

    Background: Due to overlapping histomorphological features, difference in clinical behavior and treatment response, establishing potential molecular markers to facilitate diagnosis of various genetic subtypes of diffuse gliomas is essential. Aim: To analyze 1p/19q status in diffuse gliomas and...

  • New Agents Targeting Angiogenesis in Glioblastoma. Timotheadou, Eleni // Chemotherapy Research & Practice;2011, p1 

    Glioblastoma is the most common malignant glioma in adults, and despite recent advances in standard treatment, the prognosis still remains dismal, with amedian survival of 15 months. The incorporation of bevacizumab in the standard treatment of relapsed glioblastoma has been a significant step...

  • Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Grobben, Bert; De Deyn, Peter; Slegers, Herman // Cell & Tissue Research;Dec2002, Vol. 310 Issue 3, p257 

    Infiltration of the central nervous system by neoplastic cells in patients with glioblastoma multiforme (GBM) leads to neurological dysfunction and eventually to death. The elucidation of the mechanisms underlying the aggressive nature of GBM aims at improving radio-, chemo- and gene therapy....

  • A Role for Fibrillar Collagen Deposition and the Collagen Internalization Receptor Endo180 in Glioma Invasion. Huijbers, Ivo J.; Iravani, Marjan; Popov, Sergey; Robertson, David; Al-Sarraj, Safa; Jones, Chris; Isacke, Clare M. // PLoS ONE;2010, Vol. 5 Issue 3, p1 

    Background: Glioblastoma multiforme (GBM, WHO grade IV) is the most common and most malignant of astrocytic brain tumors, and is associated with rapid invasion into neighboring tissue. In other tumor types it is well established that such invasion involves a complex interaction between tumor...

  • Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges (Review). JIN-KU LEE; DO-HYUN NAM; JEONGWU LEE // Oncology Letters;Feb2016, Vol. 11 Issue 2, p1281 

    Glioblastoma multiforme (GBM) is the most common and most lethal primary brain tumor, with tragically little therapeutic progress over the last 30 years. Surgery provides a modest benefit, and GBM cells are resistant to radiation and chemotherapy. Despite significant development of the...

  • Ishod hirur�kog lecenja malignih astrocitoma mozga. Pavlicevic, Goran; Roganovic, Zoran // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Mar/Apr2003, Vol. 60 Issue 2, p147 

    Background. The aim of this study was to analyze the outcome after the surgical treatment of patients with malignant brain astrocytomas, as well as the factors influencing the outcome. Retrospective study was performed on 145 operated patients (102 with glioblastoma multiforme, and 43 with...

  • Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, α-PIX and sorcin. Yokota, Takashi; Kouno, Jun; Adachi, Koji; Takahashi, Hiroshi; Teramoto, Akira; Matsumoto, Koshi; Sugisaki, Yuichi; Onda, Masamitsu; Tsunoda, Tatsuhiko // Acta Neuropathologica;Jan2006, Vol. 111 Issue 1, p29 

    Glioblastoma multiforme (GBM), the most malignant class of glial neoplasm (grade IV in WHO criteria), carries the worst clinical prognosis among primary brain tumors in adults. To identify a set of genes involved in the tumorigenesis of GBM, we evaluated expression profiles of GBM tissues from...

  • Radiologically Confirmed de novo Glioblastoma Multiforme and Hippocampal Sclerosis Associated with the First Onset of Nonconvulsive Simple Partial Status Epilepticus. Chang, J. W.; Chang, J. H.; Park, S. C.; Kim, T. S.; Park, Y. G.; Chung, S. S. // Acta Neurochirurgica;Apr2001, Vol. 143 Issue 3, p297 

    Summary The authors report a case of an unusual progression of glioblastoma multiforme in the temporal lobe associated with the first onset of nonconvulsive simple partial status epilepticus (SPSE), a rare form of status epilepticus. The patient underwent a left temporal craniotomy and the tumor...

  • Cell-based Immunotherapy Against Gliomas: From Bench to Bedside. Bovenberg, M Sarah S; Degeling, M Hannah; Tannous, Bakhos A // Molecular Therapy;Jul2013, Vol. 21 Issue 7, p1297 

    Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of brain tumors with a median survival of 18-21 months. Standard-of-care treatment includes maximal surgical resection of the tumor mass in combination with radiation and chemotherapy. However, as the poor survival...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics